Several viral infections were emerged in the past and become a threat to human beings. Recently, the SARS-CoV-2 had adversely affected the global population. In the last decades, other viral infections including Dengue, Chikungunya, Zika, Ebola, Japanese Encephalitis Virus (JEV), and Nipah has also been challenged the human population. Currently, the prophylaxis or vaccine candidates to combat these viral infections are in the pipeline. Diagnosing the viral infections at an early stage could be vital to control the outbreaks. Understanding the pathogenicity of the viruses and their mode of action would be also crucial. Though, designing therapeutic strategies and vaccine candidates for viral diseases are still progressing, their designs may vary between strains or variants. Translational approaches for novel therapeutic strategies and delivery systems targeting the viral proteins, host factors, and evaluating their synergistic effects need more attention.
The diagnosis of viral diseases, mainly the detection and quantification of the viral load at the initial phase of an outbreak would be critical and challenging. At the same time, lines to understand both viral and host immune responses at the beginning of a viral outbreak would abundantly contribute to novel drug discoveries. Understanding how the host factors regulate the different stages of the viral life cycle is also important for drug discoveries and vaccine designs. Additionally, dose-dependent studies and synergistic effects of already identified antiviral drugs need more consideration. Studies on the in vitro, in vivo, and in silico approaches are required before clinical investigations. During the recent SARS-Cov-2 outbreak, high throughput drug screening and drug re-purposing were the first lines of methodologies adopted before the development of vaccine candidates. The translational approaches to viral diseases enable attempts to combat viral diseases on outbreaks and that creates novel technology-based platforms for the diagnosis and drug developments. Additionally, novel delivery systems for the drug candidates need to be identified to combat the emerging viral diseases.
The Guest Editors invites original research articles, short communication, perspectives, methods, and reviews, and aim to bring together a collection of articles highlighting, but not limited to:
• Translational approaches for the detection and quantification of viruses using novel technology platforms - Qualitative and quantitative approaches, advancements to existing technologies for more accurate and timely detection of viruses, and identification of novel biomarkers
• Translational therapeutics approaches to combat viral infections (targeting both viral proteins and host factors) - High throughput screening for antiviral discoveries, molecular therapies, stem cell-based therapies, RNAi-based therapeutics, novel antiviral compounds, phytochemicals, drug re-purposing, antibodies, virus neutralization strategies, and vaccine development
• Translational approaches for novel drug delivery systems (NDDS) and adjuvant therapies in viral diseases
Several viral infections were emerged in the past and become a threat to human beings. Recently, the SARS-CoV-2 had adversely affected the global population. In the last decades, other viral infections including Dengue, Chikungunya, Zika, Ebola, Japanese Encephalitis Virus (JEV), and Nipah has also been challenged the human population. Currently, the prophylaxis or vaccine candidates to combat these viral infections are in the pipeline. Diagnosing the viral infections at an early stage could be vital to control the outbreaks. Understanding the pathogenicity of the viruses and their mode of action would be also crucial. Though, designing therapeutic strategies and vaccine candidates for viral diseases are still progressing, their designs may vary between strains or variants. Translational approaches for novel therapeutic strategies and delivery systems targeting the viral proteins, host factors, and evaluating their synergistic effects need more attention.
The diagnosis of viral diseases, mainly the detection and quantification of the viral load at the initial phase of an outbreak would be critical and challenging. At the same time, lines to understand both viral and host immune responses at the beginning of a viral outbreak would abundantly contribute to novel drug discoveries. Understanding how the host factors regulate the different stages of the viral life cycle is also important for drug discoveries and vaccine designs. Additionally, dose-dependent studies and synergistic effects of already identified antiviral drugs need more consideration. Studies on the in vitro, in vivo, and in silico approaches are required before clinical investigations. During the recent SARS-Cov-2 outbreak, high throughput drug screening and drug re-purposing were the first lines of methodologies adopted before the development of vaccine candidates. The translational approaches to viral diseases enable attempts to combat viral diseases on outbreaks and that creates novel technology-based platforms for the diagnosis and drug developments. Additionally, novel delivery systems for the drug candidates need to be identified to combat the emerging viral diseases.
The Guest Editors invites original research articles, short communication, perspectives, methods, and reviews, and aim to bring together a collection of articles highlighting, but not limited to:
• Translational approaches for the detection and quantification of viruses using novel technology platforms - Qualitative and quantitative approaches, advancements to existing technologies for more accurate and timely detection of viruses, and identification of novel biomarkers
• Translational therapeutics approaches to combat viral infections (targeting both viral proteins and host factors) - High throughput screening for antiviral discoveries, molecular therapies, stem cell-based therapies, RNAi-based therapeutics, novel antiviral compounds, phytochemicals, drug re-purposing, antibodies, virus neutralization strategies, and vaccine development
• Translational approaches for novel drug delivery systems (NDDS) and adjuvant therapies in viral diseases